---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-004795"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:33:12.542840+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; Phase 2 planned Q1 2026

## Summary
- Cohort 4: 75% of soquelitinib patients achieved EASI 75 vs 20% placebo; 25% achieved EASI 90 vs 0% placebo.
- Mean EASI reduction at day 56: 72% for soquelitinib vs 40% for placebo; separation statistically significant (p=0.035).
- No new safety signals; AE rates 41.7% soquelitinib vs 50% placebo, all Grade 1-2, no dose modifications.
- Activity seen in patients with prior systemic therapy including dupilumab/JAK inhibitors.
- Plans to initiate Phase 2 trial in moderate-to-severe atopic dermatitis in Q1 2026 (approx. 200 patients, 4 arms).

## SEC filing metadata
- accession: 0001104659-26-004795
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000110465926004795/0001104659-26-004795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000110465926004795/tm263501d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-004795
- JSON: https://secwatch.observer/filing/0001104659-26-004795.json
- Plain text: https://secwatch.observer/filing/0001104659-26-004795.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.